About 3 700 reports

Precision Immunotherapy Innovations Transforming Human Health and Wellness Executive Summary ##. ## Research Background: Innovating to Address Immunotherapies ##. ## Research Scope: Emerging Immunotherapies ##. ## Analysis Framework: Frost & Sullivan Core Value ##. ## Research Met

  • Biopharmaceutical
  • Immunotherapy
  • Medical Biotechnology
  • Therapy
  • World
  • HNC Therapeutics Market, Global, All Pipeline Products, Phase II, 2017
  • HNC Therapeutics Market, Global, All Pipeline Products, Phase I, 2017

A prime example of this is the emergence of immunotherapies and PD-##/ PD-L## targeted agents.

  • Therapy
  • Market Size
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • 3.5.1.2. PASSIVE IMMUNOTHERAPY
  • 3.5.1.1. ACTIVE IMMUNOTHERAPY

IMMUNOTHERAPIES ARE KNOWN TO PROVIDE THERAPEUTIC BENEFITS BY ONE OF THE FOLLOWING MECHANISMS: MOREOVER, IMMUNOTHERAPY MAY PREVENT RECURRENCE OF TUMOR POST-SURGERY.

  • Therapy
  • Company
  • Market Size
  • Juno Therapeutics Inc.
  • Novartis AG
  • SEGMENTATION OF GLOBAL IMMUNOTHERAPY DRUGS MARKET BY TYPE OF IMMUNOTHERAPY 2015
  • MARKET SEGMENTATION BY TYPE OF IMMUNOTHERAPY DRUG

Examples of immunotherapy drugs that target PD- ## include nivolumab (Opdivo) and pembrolizumab (Keytruda).

  • Therapy
  • World
  • AbbVie Inc.
  • Amgen Inc.
  • Merck & Co., Inc.
  • Cancer-Targeting Immunotherapy Types
  • 2.1 Immuno-Oncology: An Overview

Hoffmann-La Roche Sales by Region; 2018 ## ##.

  • Therapy
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • 8.1.1 PEANUT IMMUNOTHERAPIES
  • CLINICAL TRIAL DESIGN FOR KEY IMMUNOTHERAPY PIPELINE AGENTS IN LATE-STAGE DEVELOPMENT,

ONE OF THE MAIN BARRIERS TO THE SUCCESS OF PEANUT IMMUNOTHERAPIES THERAPIES IS THE QUESTION OF HOW THEY WILL BE REIMBURSED.

  • Therapy
  • Australia
  • World
  • Forecast
  • Aimmune Therapeutics, Inc.
  • Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Pipeline Programs Targeting Inactive Tyrosine Protein
  • STAGE OF DEVELOPMENT PRECLINICAL IND/CTA-FILED PHASE I PHASE II PHASE III PRE-REGISTRATION

Immunotherapy, which includes chemotherapy, has revolutionized cancer treatment.

  • Therapy
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Juno Therapeutics Inc.
  • Novartis AG
  • Emergence of targeted therapies and immunotherapies
  • Emergence of targeted therapies and immunotherapies

About one in ## men will die due to prostate cancer.

  • Therapy
  • Forecast
  • Astellas Pharma Inc.
  • Sanofi S.A.
  • Valeant Pharmaceuticals International, Inc.
  • SALES FORECAST BY CLASS FOR PROSTATE CANCER IN JAPAN IN 2018 AND 2028
  • SALES FORECAST BY CLASS FOR PROSTATE CANCER IN THE US IN 2018 AND 2028

ONE OF ITS MOST SUCCESSFUL DRUGS TO DATE IS THE BLOCKBUSTER ANTI-PD-## IMMUNOTHERAPY KEYTRUDA.

  • Therapy
  • East Asia
  • United States
  • Forecast
  • Pfizer Inc.
  • presents the competitive assessment of the marketed and pipeline drugs benchmarked against the SOC, topical immunotherapy
  • Current Treatment Options

I also think they may compete with topical immunotherapy. "

  • Autoimmune Disease
  • Therapy
  • United States
  • Forecast
  • Pfizer Inc.

APPENDIX ##: TABULATED DATA ##.

  • Immunotherapy
  • Medical Biotechnology
  • Therapy
  • United States
  • 9.7.2 IMMUNOTHERAPIES
  • and Figure 26. These drugs are classified into four groups: immunotherapies, second-

CURRENTLY ONLY ONE IMMUNOTHERAPY HAS BEEN APPROVED FOR USE IN MCRPC, THE CANCER VACCINE PROVENGE.

  • Hormone
  • Hospital
  • Therapy
  • Forecast
  • PROVENGE group

Thus, the rising incidence of neuroblastoma is one of the driving factors for the market growth.

  • Therapy
  • World
  • VALEANT SOLD OFF DENDREON TO
  • AS PART OF THE DEAL.

IN 2017, GILEAD SCIENCES RECEIVED FDA APPROVAL FOR YESCARTA (AXICABTAGENE CILOLEUCEL) AND HAS BECOME ONE OF THE PIONEERS IN CELL-BASED IMMUNOTHERAPY (GENE THERAPY) SINCE THEN.

  • Therapy
  • World
  • Market Size
  • Gilead Sciences, Inc.
  • Novartis AG

Global Cancer Immunotherapy Market Forecast 2019-2029 ##.

  • Cancer Immunotherapy
  • Therapy
  • World
  • Market Size
  • Retinoids Major Producer and Their Market Share
  • Demand of Skin Cancer Treatment Drugs by Region in

The auto exports exceeded over ## million each year.

  • Therapy
  • China
  • Demand
  • Bayer Schering Pharmaceutical Co., Ltd
  • Changchun ChangSheng Gene Pharmaceutical Co., Ltd.
  • Pneumonia Treatment Drugs Sales Volume by Types
  • DEMAND

Immunotherapy to prevent certain types of pneumonia is available.

  • Therapy
  • China
  • Demand
  • Harbin Pharmaceutical Group
  • North China Pharmaceutical Group Corp.
  • 46.07% of the market share comes from oncolytic virotherapy
  • MARKET SIZE AND FORECAST

GENE-INDUCED IMMUNOTHERAPY Market size and forecast MILLIONS) GLOBAL CANCER GENE THERAPY MARKET BY GENE-INDUCED IMMUNOTHERAPY 2016-2021 ($ The next-generation gene-induced immunotherapy vaccines are already in clinical trial.

  • Therapy
  • World
  • Forecast
  • Market Size
  • Celgene Corporation

Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-##, PD-L##, CTLA-##]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022 ##.

  • Oncology
  • Therapy
  • World
  • Market Size

The emergence of combination therapies and novel targets The potential advances in several areas such as immunotherapies and CGT are rekindling interest and enabling progress in the development of orphan drugs.

  • Therapy
  • North America
  • United States
  • World
  • Forecast
  • Retinoids Major Producer and Their Market Share
  • IV. SKIN CANCER TREATMENT DRUGS PRODUCTION AND

Immunotherapy Drugs Sales Volume α-Interferon Sales Volume ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Zhejiang Beisheng Medicine Industry Hansheng Pharmaceutical Co., Ltd.

  • Therapy
  • China
  • Demand
  • Bayer Schering Pharmaceutical Co., Ltd
  • Changchun ChangSheng Gene Pharmaceutical Co., Ltd.

Hoffmann-La Roche Ltd - Segment focus ## Exhibit ##: F.

  • Therapy
  • North America
  • United States
  • World

This report also excludes market size for immunotherapy.

  • Brain Cancer
  • Therapy
  • World
  • Pneumonia Treatment Drugs Sales Volume by Types
  • Pneumonia Treatment Drugs Sales Volume and Market

Immunotherapy to prevent certain types of pneumonia is available.

  • Therapy
  • China
  • Demand
  • Harbin Pharmaceutical Group
  • North China Pharmaceutical Group Corp.

Global Chronic Myelogenous Leukemia (CML) Therapeutics Market: About this market This chronic myelogenous leukemia (CML) therapeutics market analysis considers sales from targeted therapy, chemotherapy, and immunotherapy.

  • Therapy
  • World
  • Forecast
  • Market Size
  • Immunotherapy Drugs Sales Volume and Market Share by Drugs Classification (Million Yuan/percent)
  • Steroids Major Producer and Their Market Share

The auto exports exceeded over ## million each year.

  • Therapy
  • China
  • Demand
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd
  • Immunotherapy Drugs Sales Volume and Market Share by Drugs Classification (Million Yuan/percent)
  • Kidney Cancer Treatment Drugs Sales Volume by Drugs Classification in 2018(percent)

Chapter IV KIDNEY CANCER TREATMENT DRUGS PRODUCTION AND DEMAND Chart ##: Immunotherapy Drugs Sales Volume (million Yuan) The Immunotherapy Drugs contains two different kinds, and they are cytokines and cancer vaccines.

  • Therapy
  • China
  • Demand
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd
  • Market definition
  • Biopsy

Interferon alfa, one of the initial treatments for Kaposi sarcoma, is an example of immunotherapy.

  • Therapy
  • Forecast
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • 8.1.2 APPLICATION OF CELLULAR IMMUNOTHERAPY
  • presents clinical trial designs for CMV cellular immunotherapy.

Oxford University Press, ## Suppl ##(Suppl ##), pp.

  • Therapy
  • Japan
  • United States
  • Atara Biotherapeutics, Inc.
  • Moderna Therapeutics, Inc.
  • T-cell Immunotherapy Number of Molecules in Preclinical Development
  • Scenario Comparison: Share of Sub-segments

Note on Confidentiality Contents T-cell Immunotherapy: An Introduction ## ## Market Overview Market Forecast: Scenario Comparison T-cell Immunotherapy: An Introduction## Growing Clinical Pipeline The Primary Growth Driver With no marketed products, this emerging field is still in its

  • Medical Biotechnology
  • Therapy
  • United States
  • Market Size
  • Kite Pharma, Inc.